Please enter keyword
OK
Please enter keyword
OK
Introduction to the Biocytogen Animal Center
Since 2014, Biocytogen has been operating three animal centers distributed in Nantong (Jiangsu, P.R.China), Daxing (Beijing, P.R.China), and Boston (USA) under the brand of "Biocytogen Animals". The ultimate goal is to provide superior supports to global customers for their scientific research as well as new drug discovery using our innovative genetically engineered models (GEMs). Through implementing strict, scientific, and standard operating procedures, and a highly efficient facility management system, the animal centers have performed the same or even higher standards for critical quality-control testing to identify microbial contamination. With innovative animal models, high standard quality-control program, and tailored services, the animal centers have contributed significant shares of Biocytogen to support and promote the rapid growth of the biopharma industry throughout the world.
920+
Number of strains
20+
Number of partners
2times
AAALAC certification
110thousand
Rat / Mouse cage position
43000
Area covered
Certifications
AAALAC certificate
Laboratory animal productio...
Laboratory animal use permi...
New high-tech enterprise
Animal export qualification
More
Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany.
More